342 related articles for article (PubMed ID: 23232273)
1. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
2. Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer.
Baek S; Choi CM; Ahn SH; Lee JW; Gong G; Ryu JS; Oh SJ; Bacher-Stier C; Fels L; Koglin N; Hultsch C; Schatz CA; Dinkelborg LM; Mittra ES; Gambhir SS; Moon DH
Clin Cancer Res; 2012 Oct; 18(19):5427-37. PubMed ID: 22893629
[TBL] [Abstract][Full Text] [Related]
3. Utility of [
Kavanaugh G; Williams J; Morris AS; Nickels ML; Walker R; Koglin N; Stephens AW; Washington MK; Geevarghese SK; Liu Q; Ayers D; Shyr Y; Manning HC
Mol Imaging Biol; 2016 Dec; 18(6):924-934. PubMed ID: 27677886
[TBL] [Abstract][Full Text] [Related]
4. Exploratory Clinical Investigation of (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate PET of Inflammatory and Infectious Lesions.
Chae SY; Choi CM; Shim TS; Park Y; Park CS; Lee HS; Lee SJ; Oh SJ; Kim SY; Baek S; Koglin N; Stephens AW; Dinkelborg LM; Moon DH
J Nucl Med; 2016 Jan; 57(1):67-9. PubMed ID: 26471694
[TBL] [Abstract][Full Text] [Related]
5. Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.
Koglin N; Mueller A; Berndt M; Schmitt-Willich H; Toschi L; Stephens AW; Gekeler V; Friebe M; Dinkelborg LM
Clin Cancer Res; 2011 Sep; 17(18):6000-11. PubMed ID: 21750203
[TBL] [Abstract][Full Text] [Related]
6. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.
Mittra ES; Koglin N; Mosci C; Kumar M; Hoehne A; Keu KV; Iagaru AH; Mueller A; Berndt M; Bullich S; Friebe M; Schmitt-Willich H; Gekeler V; Fels LM; Bacher-Stier C; Moon DH; Chin FT; Stephens AW; Dinkelborg LM; Gambhir SS
PLoS One; 2016; 11(2):e0148628. PubMed ID: 26890637
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of (4S)-4-(3-
Cheng MF; Huang YY; Ho BY; Kuo TC; Hsin LW; Shiue CY; Kuo HC; Jeng YM; Yen RF; Tien YW
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):810-820. PubMed ID: 30635754
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
9. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
[TBL] [Abstract][Full Text] [Related]
10. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
Pant V; Sen IB; Soin AS
Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
[TBL] [Abstract][Full Text] [Related]
11. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
[TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
13. Initial evaluation of (4S)-4-(3-[
Park SY; Mosci C; Kumar M; Wardak M; Koglin N; Bullich S; Mueller A; Berndt M; Stephens AW; Chin FT; Gambhir SS; Mittra ES
EJNMMI Res; 2020 Aug; 10(1):100. PubMed ID: 32857284
[TBL] [Abstract][Full Text] [Related]
14.
Wardak M; Sonni I; Fan AP; Minamimoto R; Jamali M; Hatami N; Zaharchuk G; Fischbein N; Nagpal S; Li G; Koglin N; Berndt M; Bullich S; Stephens AW; Dinkelborg LM; Abel T; Manning HC; Rosenberg J; Chin FT; Gambhir SS; Mittra ES
Radiology; 2022 Jun; 303(3):620-631. PubMed ID: 35191738
[TBL] [Abstract][Full Text] [Related]
15. (S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry.
Smolarz K; Krause BJ; Graner FP; Wagner FM; Hultsch C; Bacher-Stier C; Sparks RB; Ramsay S; Fels LM; Dinkelborg LM; Schwaiger M
J Nucl Med; 2013 Jun; 54(6):861-6. PubMed ID: 23568366
[TBL] [Abstract][Full Text] [Related]
16. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
17. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.
Takemoto K; Hatano E; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Matsumura K; Zaima M; Toriguchi K; Tanabe K; Kitamura K; Seo S; Taura K; Endo K; Uemoto S; Higashi T
Ann Nucl Med; 2014 May; 28(4):371-80. PubMed ID: 24599824
[TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
19. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
Ho CL; Yu SC; Yeung DW
J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
[TBL] [Abstract][Full Text] [Related]
20. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL
Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
